Nasdaq GlobeNewswire

Taconic Biosciences Sponsors Custom Model to Support Kabuki Syndrome, a Rare Disorder Causing Intellectual Disability

Del

HUDSON, N.Y., Aug. 31, 2017 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in genetically engineered rodent models and associated services, is funding the development of a custom mouse model to study Kabuki syndrome, a rare genetic disorder. Taconic is donating model generation services as a third-time sponsor of the Rare Disease Science Challenge, BeHEARD. Hosted by the Rare Genomics Institute, the Rare Disease Science Challenge is an annual event in which industry sponsors donate services to accelerate rare disease research.

Characterized by mild to moderate intellectual disability, stunted growth, immune dysregulation, and hearing loss, Kabuki syndrome is caused by mutations in the KMT2D or KDM6Agenes. Taconic will use CRISPR/Cas 9 gene editing technology to develop the first Kmt2d missense mouse model of Kabuki syndrome and generate a cohort of mice for study. In parallel, Taconic will cryopreserve and store the mouse line.

"Taconic recognizes the vital role mouse models play in understanding the mechanisms of rare diseases and the challenges of funding their research," said Bob Rosenthal, CEO, Taconic Biosciences. "Taconic is committed to advancing rare disease research through efforts such as sponsorship of the BeHEARD challenge and donation of an integrated solution of model generation, breeding and cryopreservation capabilities."

Teresa Luperchio, PhD, a postdoctoral fellow in the laboratory of Hans Bjornsson, MD, PhD, director of the Epigenetics and Chromatin Clinic, McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, will employ the Taconic model. Dr. Bjornsson's lab previously characterized a mouse model carrying a loss-of-function variant of the Kmt2d gene and demonstrated reversal of some learning and memory deficits using therapeutic strategies. However, the initial mouse line models only a subset of individuals with Kabuki syndrome. Taconic will generate a Kabuki syndrome mouse model based on a patient-specific missense mutation. This will enable investigators to assess whether therapies they are developing can reverse disability in a wider spectrum of the Kabuki syndrome patient population.    

"The model will be invaluable in moving the field closer to treating what has been viewed as an untreatable disorder. Experience with our first mouse model showed that for patients with the KMT2D mutation, the disease may be treatable in humans," Dr. Bjornsson said. "We hope the Taconic model will demonstrate this capability in an expanded patient population, allowing us to employ a single therapeutic strategy for all Kabuki syndrome type 1 patients." 

"Taconic's ability to develop a patient-specific model was essential. Generating a model that closely represents what is seen in patients is critical for translating our findings from the bench to the clinic," Dr. Luperchio says.

To learn more about Taconic's custom model generation, please call 1-888-TACONIC (888-822-6642) in the US or +45 70 23 04 05 in Europe, or email info@taconic.com.

To learn about the BeHEARD Project, visit http://www.raregenomics.org/beheard-competition/.

About Taconic Biosciences, Inc.
Taconic Biosciences is a global leader in genetically engineered rodent models and services. Founded in 1952, Taconic helps biotechnology companies and institutions acquire, custom generate, breed, precondition, test, and distribute valuable research models worldwide. Specialists in genetically engineered mouse and rat models, precision research mouse models, and integrated model design and breeding services, Taconic operates three service laboratories and six breeding facilities in the U.S. and Europe, maintains distributor relationships in Asia and has global shipping capabilities to provide animal models almost anywhere in the world.

Media Contact:
Kelly Owen Grover
Director of Marketing Communications
(518) 697-3824
kelly.grover@taconic.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Taconic Biosciences via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

AnGes Submits Application for Marketing Approval to PMDA for HGF gene therapy for Critical Limb Ischemia23.1.2018 04:44Pressemelding

TOKYO, Jan. 23, 2018 (GLOBE NEWSWIRE) -- AnGes, Inc., a biopharmaceutical company focused on developing innovative gene-based medicines for serious diseases, announced today the submission of an application for marketing approval to the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan for HGF plasmid, an investigational gene therapy for the treatment of critical limb ischemia (CLI), the most severe condition of peripheral arterial disease. The submission is based on the positive results from the randomized, placebo-controlled phase 3 trial and investigator-led clinical study conducted in Japan. AnGes anticipates being granted conditional approval under the regulatory scheme of "Approval with Conditions and Time Limit" for regenerative medicines. The review process is expected to take approximately one year. HGF plasmid has the potential to be one of the first gene therapy products to be approved for a non-genetic disease with chronic conditions. AnGes grants to Mitsubishi Tan

SEMAFO Inc. : Q4 and Annual 2017 Production and Costs in Line23.1.2018 00:59Pressemelding

Boungou 80% Complete - Continues on Time, on Budget MONTREAL, Jan. 22, 2018 (GLOBE NEWSWIRE) -- SEMAFO Inc. (TSX:SMF) (OMX:SMF) reports 2017 production of 206,400 ounces at an all-in sustaining cost of $943 per ounce. As a result, the Corporation has beat its revised production and met its cost guidance for the year. Mana In the fourth quarter, Mana produced 49,500 ounces of gold at a total cash cost1 of $667 per ounce and all-in sustaining cost2 of $987 per ounce Annual production of 206,400 ounces, slightly ahead of 2017 guidance of 190,000 to 205,000 ounces Total cash cost1 for 2017 of $655 per ounce All-in sustaining cost2 for 2017 of $943 per ounce, in line with guidance of $920 to $960 per ounce Gold sales of 205,300 ounces generated 2017 revenues of $259 million ($1,261 per ounce) Mining Operations Mana, Burkina Faso Three-month period Year ended December 31, ended December 31, 2017 2016 Variation 2017 2016 Variation Tonnes processed 653,500 714,200 (8%) 2,739,900 2,753,300 - He

Atico Reports 2017 Fourth Quarter and Full Year Production Results22.1.2018 22:30Pressemelding

VANCOUVER, British Columbia, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Atico Mining Corporation (the "Company" or "Atico") (TSXV:ATY) (OTC:ATCMF) is pleased to announce operating results for the three and twelve month periods ended December 31, 2017 from its El Roble mine. Production totaled 5.33 million pounds of copper with 2,972 ounces of gold for the fourth quarter ("Q4 2017") and 20.63 million pounds of copper with 10,923 ounces of gold in concentrates for the full year 2017. "Atico has successfully concluded its fourth full year of operating the El Roble mine, exceeding 2017 guidance while achieving the highest annual production results to date," said Fernando E. Ganoza, CEO. "In the upcoming year, we will focus on increasing mineral resources through aggressive exploration at the El Roble mine and the surrounding prospective 6,600 hectare land package, to continue growing production and expanding the operation." Fourth Quarter and Full Year Operational Highlights Fourth Quarter Producti

Banque Fédérative du Credit Mutuel: Post Stabilisation Notice22.1.2018 18:54Pressemelding

PARIS, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Banque Fédérative du Credit Mutuel Post Stabilisation Notice HSBC (contact: Syndicate desk, telephone: +44 207 992 8066) hereby gives notice that no stabilisation (within the meaning of the rules of the Financial Conduct Authority) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities. Issuer: Banque Fédérative du Credit Mutuel Guarantor (if any): na Aggregate nominal amount: GBP 450,000,000 Description: 1.375% due Dec 2021 Offer price: 99.872 Stabilising Managers: HSBC & Goldman Sachs This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction This information is provided by RNS The company news service from the London Stock Exchange Contacts: RNS Customer Services 0044-207797-4400 rns@londonstockexchange.com http://www.rns.com This announ

Claroty Wins Inaugural S4 ICS Detection Challenge22.1.2018 18:42Pressemelding

Product Takes Top Spot in both Asset Discovery and Threat Detection Phases NEW YORK, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Claroty, an innovator in operational technology (OT) network protection, today announced that it was crowned winner of the inaugural S4 ICS Detection Challenge, which took place at the S4x18 Conference in Miami. Claroty's Continuous Threat Detection product claimed top honors in both the Phase I - Identification and Phase II - Detection segments of the challenge. During Phase I, contestants consumed network traffic captured from 15 different sites at an unidentified West Coast (U.S.) oil and gas company. The contestants were required to use their products to identify industrial control system (ICS) assets on the network and provide a view of how the assets were communicating. Contestants were rewarded for discovering assets, identifying specific details about them and were given bonus points for unique insights. Scoring was designed to test the products themselves, rat

CEO optimism booms despite increasing anxiety over threats to growth22.1.2018 18:30Pressemelding

· Optimism in global economic growth reaches record level and rises in all countries · US reinforces its lead on China as a target market for growth in 2018 · Over half of CEOs expect their headcount to increase · Terrorism, geopolitical uncertainty, cyber and climate change rise as threats to growth DAVOS, Switzerland, Jan. 22, 2018 (GLOBE NEWSWIRE) -- A record-breaking share of CEOs are optimistic about the economic environment worldwide, at least in the short term. That's one of the key findings of PwC's 21st survey of almost 1,300 CEOs around the world, launched today at the World Economic Forum Annual Meeting in Davos. Fifty seven percent of business leaders say they believe global economic growth will improve in the next 12 months. It's almost twice the level of last year (29%) and the largest ever increase since PwC began asking about global growth in 2012. Optimism in global growth has more than doubled in the US (59%) after a period of uncertainty surrounding the election (201

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom